Viracta Therapeutics, Inc. - FORM 10-Q - EX-10.2 - SUMMARY OF NON-EMPLOYEE DIRECTOR CASH COMPENSATION ARRANGEMENTS - August 13, 2010

Attached files

file	filename
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A) - Viracta Therapeutics, Inc.	dex311.htm
EX-32.1 - CERTIFICATION OF CEO AND CFO PURSUANT TO 13A-14(B) OR 15D-14(B) - Viracta Therapeutics, Inc.	dex321.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A) - Viracta Therapeutics, Inc.	dex312.htm
10-Q - FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2010 - Viracta Therapeutics, Inc.	d10q.htm

Exhibit 10.2

Summary of Non-Employee Director Cash Compensation Arrangements


Annual Cash Retainer		$	30,000
Annual Audit Committee Chair Fee		$	10,000
Annual Compensation and Nominating and Corporate Governance Committee Chairs Fee		$	7,500
Annual Committee Fee		$	5,000